You got a problem with it, talk to the shelter. “Listen, the lady at the shelter approved my application. He pretends like my words are an insult to him and his dog. There were a few burglaries in the neighborhood and we need a good watchdog.”
I didn’t get her for some retaliation against you. “So you steal the one dog at the shelter you know I have a special attachment to just to piss me off and rub it in?” “This whole adopting thing isn’t really about Granny. Granny and I are bondin’.” He crosses his fingers. He’s doing his best to upset me and it’s working. “Yeah, so? You know the sayin’ … you snooze, you lose. “How can I steal a dog I officially adopted at a shelter?” I’m careful not to step in anything unidentifiable, but since the bushes are in the way, it’s no use. You might want to be careful where you step.”Įww. He looks at me, and I give him the universal sign language for “open the damn door” by pointing to it.īy the time I shimmy back to the front stoop, he’s opened the door. I eye Luis sitting on the couch with Granny in his lap, then knock on the glass to get his attention. I shimmy through the space between the bushes and the front window. I put my ear to the door and hear the television, so I know someone’s got to be home.
After I clock out, I get in my car and race to Luis’s house. My mind is in a rage as I spend my assigned time cleaning out cages and walking the dogs. Oh, how could I ever have thought I wanted to be with someone who’d adopt a dog just for revenge? “Your friend came in right before we closed last night and adopted her,” one of the other volunteers tells me. Orphan drug designation provides incentives to assist and encourage drug development for rare diseases.Until I look at the bottom of the page at the name of the person who adopted her. People who could be pregnant should be tested for pregnancy before using Besremi due to the risk of fetal harm.īesremi received orphan drug designation for this indication. Patients who must not take Besremi include those who are allergic to the drug, those with a severe psychiatric disorder or a history of a severe psychiatric disorder, immunosuppressed transplant recipients, certain patients with autoimmune disease or a history of autoimmune disease, and patients with liver disease. Interferon alfa products like Besremi may cause or worsen neuropsychiatric, autoimmune, ischemic (not enough blood flow to a part of the body) and infectious diseases, which could lead to life-threatening or fatal complications. Side effects may also include urinary tract infection, depression and transient ischemic attacks (stroke-like attacks). Overall, 61% of patients had a complete hematological response.īesremi can cause liver enzyme elevations, low levels of white blood cells, low levels of platelets, joint pain, fatigue, itching, upper airway infection, muscle pain and flu-like illness. Besremi’s effectiveness was assessed by looking at how many patients achieved complete hematological response, which meant that patients had a red blood cell volume of less than 45% without a recent phlebotomy, normal white cell counts and platelet counts, a normal spleen size, and no blood clots. In this trial, 51 adults with polycythemia vera received Besremi for an average of about five years.
CHUY BLOOD IN BLOOD OUT TRIAL
The effectiveness and safety of Besremi were evaluated in a multicenter, single-arm trial that lasted 7.5 years. If Besremi can reduce excess blood cells and maintain normal levels for at least one year, then dosing frequency may be reduced to once every four weeks.
CHUY BLOOD IN BLOOD OUT SKIN
Besremi is a long-acting drug that patients take by injection under the skin once every two weeks. Besremi is believed to work by attaching to certain receptors in the body, setting off a chain reaction that makes the bone marrow reduce blood cell production. Treatment for polycythemia vera includes phlebotomies (a procedure that removes excess blood cells though a needle in a vein) as well as medicines to reduce the number of blood cells Besremi is one of these medicines. “This action highlights the FDA’s commitment to helping make new treatments available to patients with rare diseases.”īesremi is the first FDA-approved medication for polycythemia vera that patients can take regardless of their treatment history, and the first interferon therapy specifically approved for polycythemia vera. Polycythemia vera affects approximately 6,200 Americans each year,” said Ann Farrell, M.D., director of the Division of Non-Malignant Hematology in the FDA’s Center for Drug Evaluation and Research. “Over 7,000 rare diseases affect more than 30 million people in the United States.
The excess cells thicken the blood, slowing blood flow and increasing the chance of blood clots. Food and Drug Administration approved Besremi (ropeginterferon alfa-2b-njft) injection to treat adults with polycythemia vera, a blood disease that causes the overproduction of red blood cells.
0 kommentar(er)
